Characterization of Genetic Variants Associated with Rifampicin Resistance Level in Mycobacterium tuberculosis Clinical Isolates Collected in Guangzhou Chest Hospital, China

References

• Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol. 1996;33(3):167–175. doi:10.1007/s002849900095
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Zhang H, Liu X, Xu C, et al. Guiding tuberculosis control through the healthy China initiative 2019–2030. China CDC Wkly. 2020;2(49):948–950. doi:10.46234/ccdcw2020.236
   Google Scholar
• Su W, Ruan Y, Li T, Du X, Jiang J, Li R. Characteristics of rifampicin-resistant tuberculosis detection in China, 2015–2019. Infect Dis Pov. 2021;10(1):99. doi:10.1186/s40249-021-00883-8
   Web of Science ®Google Scholar
• Yan-mei CHEN, Hui-zhong WU, Liu-yue XU, Ke-hao PENG, Mei-ling YU. Analysis of monitoring results of tuberculosis drug-resistance in Guangdong province from 2016 to 2020. Chinese J of Antituber. 2022;44(7):685–689. doi:10.19982/j.issn.1000-6621.20220028
   Google Scholar
• Loots DT. New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2015;71(3):655–660. doi:10.1093/jac/dkv406
   Web of Science ®Google Scholar
• Andre E, Goeminne L, Cabibbe A, et al. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23(3):167–172. doi:10.1016/j.cmi.2016.09.006
   PubMed Web of Science ®Google Scholar
• Hameed HMA, Islam MM, Chhotaray C, et al. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol. 2018;8:114. doi:10.3389/fcimb.2018.00114
   Web of Science ®Google Scholar
• Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med. 2009;103(12):1777–1790. doi:10.1016/j.rmed.2009.07.010
   Web of Science ®Google Scholar
• Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84. doi:10.1016/S1473-3099(17)30691-6
   PubMed Web of Science ®Google Scholar
• Lawn SD, Nicol MP. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–1082. doi:10.2217/fmb.11.84
   PubMed Web of Science ®Google Scholar
• André E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmée M. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2017;23(4):267. e5–267. e7. doi:10.1016/j.cmi.2016.12.009
   Web of Science ®Google Scholar
• Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181–1182. doi:10.1056/NEJMc1413930
   PubMed Web of Science ®Google Scholar
• Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep. 2016;6:25330. doi:10.1038/srep25330
   PubMed Web of Science ®Google Scholar
• Hameed HA, Tan Y, Islam MM, et al. Detection of novel gene mutations associated with pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates in southern China. Infect Drug Resist. 2020;13:217. doi:10.2147/IDR.S230774
   PubMed Web of Science ®Google Scholar
• Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect. 2018;25:1041.e1–1041.e7. doi:10.1016/j.cmi.2018.12.008
   Web of Science ®Google Scholar
• World Health organization. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: World Health Organization; 2008.
   Google Scholar
• World Health organization. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. World Health Organization; 2018.
   Google Scholar
• Islam MM, Tan Y, Hameed HMA, et al. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China. J Glob Antimicrob. 2020;22:290–295. doi:10.1016/j.jgar.2020.02.019
   Web of Science ®Google Scholar
• Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother. 1997;41(5):1004–1009. doi:10.1128/AAC.41.5.1004
   PubMed Web of Science ®Google Scholar
• Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48(1):229–237. doi:10.1128/jcm.01463-09
   PubMed Web of Science ®Google Scholar
• Uddin MKM, Rahman A, Ather MF, et al. Distribution and frequency of rpoB mutations detected by Xpert MTB/RIF assay among Beijing and Non-Beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect Drug Resist. 2020;13:789–797. doi:10.2147/IDR.S240408
   Web of Science ®Google Scholar
• Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2014;7(2):75–91. doi:10.1016/j.jiph.2013.09.001
   PubMed Web of Science ®Google Scholar
• Jnawali HN, Hwang SC, Park YK, et al. Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn Microbiol Infect Dis. 2013;76(2):187–196. doi:10.1016/j.diagmicrobio.2013.02.035
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang M, Wang J, et al. Longitudinal analysis of prevalence and risk factors of rifampicin-resistant tuberculosis in Zhejiang, China. Biomed Res Int. 2020:3159482. doi:10.1155/2020/3159482
   Web of Science ®Google Scholar
• Minh NN, Van BN, Son NT, et al. Molecular characteristics of rifampin-and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam. J Clin Microbiol. 2012;50(3):598–601. doi:10.1128/JCM.05171-11
   Web of Science ®Google Scholar
• Huang H, Zhang Y, Li S, et al. Rifampicin resistance and multidrug-resistant tuberculosis detection using Xpert MTB/RIF in Wuhan, China: a retrospective study. Microb Drug Resist. 2017;24(5):675–679. doi:10.1089/mdr.2017.0114
   Web of Science ®Google Scholar
• Farhat MR, Sultana R, Iartchouk O, et al. Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. Am J Respir Crit Care Med. 2016;194(5):621–630. doi:10.1164/rccm.201510-2091OC
   Web of Science ®Google Scholar
• Kozhamkulov U, Akhmetova A, Rakhimova S, et al. Molecular Characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan. Jpn J Infect Dis. 2011;64(3):253–255. doi:10.7883/yoken.64.253
   Web of Science ®Google Scholar
• Lin YH, Tai CH, Li CR, Lin CF, Shi ZY. Resistance profiles and rpoB gene mutations of Mycobacterium tuberculosis isolates in Taiwan. J Microbiol Immunol Infect. 2013;46(4):266–270. doi:10.1016/j.jmii.2012.06.008
   Google Scholar
• Jing W, Pang Y, Zong Z, et al. Rifabutin resistance associated with double mutations in rpoB gene in Mycobacterium tuberculosis isolates. Front Microbiol. 2017;8(1768). doi:10.3389/fmicb.2017.01768
   Web of Science ®Google Scholar
• Prasad PG, Jasmine MS, Deepthi K, Allam US, Allam US. Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India. Braz J Infect Dis. 2019;23:281–290. doi:10.1016/j.bjid.2019.07.002
   Web of Science ®Google Scholar
• Rukasha I, Said HM, Omar SV, et al. Correlation of rpoB Mutations with minimal inhibitory concentration of rifampin and rRifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa. Front Microbiol. 2016;7(1947). doi:10.3389/fmicb.2016.01947
   Web of Science ®Google Scholar
• Valim ARM, Rossetti MLR, Ribeiro MO, Zaha A. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin Microbiol. 2000;38(8):3119–3122. doi:10.1128/JCM.38.8.3119-3122.2000
   Web of Science ®Google Scholar
• Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46(3):279–286. doi:10.1038/ng.2878
   PubMed Web of Science ®Google Scholar
• Poudel A, Nakajima C, Fukushima Y, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrob Agents Chemother. 2012;56(6):2831–2836. doi:10.1128/AAC.06418-11
   Web of Science ®Google Scholar
• Rahim Z, Nakajima C, Raqib R, et al. Molecular mechanism of rifampicin and isoniazid resistance in Mycobacterium tuberculosis from Bangladesh. Tuberculosis. 2012;92(6):529–534. doi:10.1016/j.tube.2012.07.005
   PubMed Web of Science ®Google Scholar
• Tang K, Sun H, Zhao Y, et al. Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. Tuberculosis. 2013;93(1):89–95. doi:10.1016/j.tube.2012.10.009
   Web of Science ®Google Scholar
• Luo T, Zhao M, Li X, et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother. 2010;54(3):1075–1081. doi:10.1128/AAC.00964-09
   PubMed Web of Science ®Google Scholar
• M-c L, Lu J, Lu Y, et al. rpoB mutations and effects on rifampin resistance in Mycobacterium tuberculosis. Infect Drug Resist. 2021;14:4119. doi:10.2147/IDR.S333433
   Web of Science ®Google Scholar
• Wan L, Liu H, Li M, et al. Genomic analysis identifies mutations concerning drug-resistance and Beijing genotype in multidrug-resistant Mycobacterium tuberculosis isolated from China. Front Microbiol. 2020;11:1444. doi:10.3389/fmicb.2020.01444
   Web of Science ®Google Scholar
• Hameed HMA, Tan Y, Islam MM, et al. Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China. J Thorac Dis. 2019;11(11):4613–4625. doi:10.21037/jtd.2019.11.03
   Web of Science ®Google Scholar
• Feuerriegel S, Oberhauser B, George AG, et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol. 2012;12(1):90. doi:10.1186/1471-2180-12-90
   PubMed Web of Science ®Google Scholar
• Shea J, Halse TA, Kohlerschmidt D, et al. Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol. 2021;59(4):e01885–20. doi:10.1128/JCM.01885-20
   PubMed Web of Science ®Google Scholar
• Cavusoglu C, Karaca‐Derici Y, Bilgic A. In‐vitro activity of rifabutin against rifampicin‐resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect. 2004;10(7):662–665. doi:10.1111/j.1469-0691.2004.00917.x
   Web of Science ®Google Scholar
• Jamieson F, Guthrie J, Neemuchwala A, Lastovetska O, Melano R, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52(6):2157–2162. doi:10.1128/JCM.00691-14
   PubMed Web of Science ®Google Scholar
• Phelan J, Coll F, McNerney R, et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med. 2016;14(1):31. doi:10.1186/s12916-016-0575-9
   PubMed Web of Science ®Google Scholar
• Jagielski T, Bakuła Z, Brzostek A, et al. Characterization of mutations conferring resistance to rifampin in Mycobacterium tuberculosis clinical strains. Antimicrob Agents Chemother. 2018;62(10):e01093–e0118. doi:10.1128/AAC.01093-18
   PubMed Web of Science ®Google Scholar